Challenge
A client transitioning from clinical to commercial manufacturing for a complex gene therapy needed to balance cost and supply risk. Goals included reducing CMO dependence, lowering operational complexity, gaining capacity flexibility, and managing supply risk across commercial and clinical demand.
Approach
We analyzed the current supply network across cost, risk, and flexibility, developed future network options with demand scenarios, and built a five-year investment model covering both drug and vector manufacturing.
Impact
We delivered a clear 5-year network strategy backed by robust analysis, ready for immediate execution — reducing manufacturing capacity costs by 25% while managing supply risk and maintaining required service levels.
